Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program
Stock Information for Awakn Life Sciences
Loading
Please wait while we load your information from QuoteMedia.